Cardiovascular MRI beats SPECT in diagnosing heart disease, according to the authors of a major British study published online on Dec. 23 in The Lancet.
Cardiovascular MRI beats SPECT in diagnosing heart disease, according to the authors of a major British study published online on Dec. 23 in The Lancet.
A team led by John Greenwood, MD, of the Leeds General Infirmary recruited 752 patients at two British hospitals from March 2006 through August 2009 in a $2 million study funded by the British Health Foundation.
In the prospective trial, called CE-MARK, patients with suspected heart disease and at least one cardiovascular risk factor were given cardiovascular MRI, SPECT, and invasive x-ray coronary angiography.
The researchers considered the relative sensitivity, specificity, and predictive value (positive as well as negative) of MRI and SPECT. Coronary angiography showed significant coronary heart disease in 39 percent of the cohort.
The sensitivity of MRI (86.5 percent) was higher than that of SPECT (66.5 percent). Specificity (83.4 percent for MRI versus 82.6 percent for SPECT) and positive predictive value (77.2 percent for MRI vs. 71.4 percent for SPECT) were comparable. MRI outperformed SPECT in negative predictive value (90.5 percent vs. 79.1 percent).
In view of what they described as cardiovascular MRI’s “superiority over SPECT,” Greenwood and colleagues concluded that cardiovascular MRI “should be adopted more widely than at present for the investigation of coronary heart disease.”
FDA Clears Remote Scanning Support Platform for MRI, CT and PET/CT
March 25th 2024The multimodality system nCommand Lite reportedly facilitates real-time remote imaging guidance on scanning parameters and procedure assessments to licensed technologists for a variety of imaging modalities including CT and MRI.
Study: PET/MRI May Prevent Up to 83 Percent of Unnecessary Biopsies in Men with PI-RADS 3 Lesions
March 15th 2024For men with PI-RADS 3 lesions, PRIMARY scores of 4-5 with PET/MRI had a sensitivity rate of 87.5 percent for clinically significant prostate cancer, according to newly published research.